FFO
AVDL

Fortitude Family Office’s Avadel Pharmaceuticals AVDL Stock Holding History

Fortitude Family Office’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-55
Closed -$487 – 1996
2025
Q2 		$487 Buy
+55
New +$483 ﹤0.01% 1829

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Fortitude Family Office's AVDL Position: Q3 2025 in Review

Fortitude Family Office sold out of Avadel Pharmaceuticals (AVDL) in Q3 2025, closing a stake of 55 shares — an estimated $487 sold.

Fortitude Family Office first reported a position in AVDL in Q2 2025 and held it in 1 quarter. The position peaked at $487 in Q2 2025. 188 funds tracked by Wall St. Rank hold AVDL as of Q3 2025.

  • Fortitude Family Office reported no remaining Avadel Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Fortitude Family Office sold 55 Avadel Pharmaceuticals shares in Q3 2025, an estimated $487.
  • Fortitude Family Office first reported a position in Avadel Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Fortitude Family Office's Avadel Pharmaceuticals position peaked at $487 in Q2 2025.
  • 188 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2025.

Based on Fortitude Family Office's 13F filing for Q3 2025, filed 17 Oct 2025.